Redeye's view is that Lagercrantz reported another strong quarter in a challenging market. Lagercrantz are benefitting from strong acquired growth and again showed positive organic growth. We increase our fair value range and believe Lagercrantz is set for continued good profit growth in line with its financial targets of growing earnings per share by 15% per year.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/